{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:22:21Z","timestamp":1758637341401,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T01:55:24Z","timestamp":1520474124000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poids atropinique et m\u00e9dicaments anticholinergiques\u00a0: int\u00e9r\u00eat et application en pratique clinique chez la personne \u00e2g\u00e9e"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-196X","authenticated-orcid":false,"given":"Sibylle","family":"de Germay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2018.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","article-title":"Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study","volume":"59","author":"Fox","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.02.010_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2004.02232.x","article-title":"Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study","volume":"59","author":"Lechevallier-Michel","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinte.167.8.781","article-title":"A drug burden index to define the functional burden of medications in older people","volume":"167","author":"Hilmer","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2018.02.010_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","article-title":"Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis","volume":"80","author":"Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jalz.2012.02.005","article-title":"Long-term anticholinergic use and the aging brain","volume":"9","author":"Cai","year":"2013","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.therap.2018.02.010_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.3624","article-title":"Associations of drug burden index with falls, general practitioner visits and mortality in older people","volume":"23","author":"Nishtala","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2018.02.010_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000000195","article-title":"Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort","volume":"34","author":"Dauphinot","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0040","doi-asserted-by":"crossref","first-page":"e83224","DOI":"10.1371\/journal.pone.0083224","article-title":"Impact of high-risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study","volume":"9","author":"Gnjidic","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.therap.2018.02.010_bib0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40266-017-0475-5","article-title":"Risk of mortality associated with anticholinergic use in elderly nursing home residents with depression","volume":"34","author":"Chatterjee","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.therap.2018.02.010_bib0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.1997.00440350031003","article-title":"Explicit criteria for determining potentially inappropriate medication use by the elderly. an update","volume":"157","author":"Beers","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2018.02.010_bib0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00228-007-0324-2","article-title":"Potentially inappropriate medications in the elderly: a French consensus panel list","volume":"63","author":"Laroche","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0060","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","article-title":"The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries","volume":"71","author":"Renom-Guiteras","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0065","series-title":"Goodman and Gilman: the pharmacological basis of therapeutics","first-page":"219","article-title":"Muscarinic receptor agonists antagonists","author":"Joan","year":"2011"},{"key":"10.1016\/j.therap.2018.02.010_bib0070","series-title":"Diversit\u00e9 des r\u00e9cepteurs et des effets cholinergiques. Pharmacologie\u00a0: des cibles \u00e0 la th\u00e9rapeutique","first-page":"279","author":"Landry","year":"2014"},{"key":"10.1016\/j.therap.2018.02.010_bib0075","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00228-013-1499-3","article-title":"Systematic review of anticholinergic risk scales in older adults","volume":"69","author":"Dur\u00e1n","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archpsyc.1980.01780160063007","article-title":"Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects","volume":"37","author":"Tune","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.therap.2018.02.010_bib0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40266-015-0321-6","article-title":"Central anticholinergic adverse effects and their measurement","volume":"32","author":"Lampela","year":"2015","journal-title":"Drugs aging"},{"key":"10.1016\/j.therap.2018.02.010_bib0090","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0095","first-page":"131","article-title":"\u00c9chelles d\u2019\u00e9valuation de l\u2019effet anticholinergique des m\u00e9dicaments","volume":"12","author":"Mebarki","year":"2012","journal-title":"NPG"},{"key":"10.1016\/j.therap.2018.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2015.10.002","article-title":"Systematic review on the use of anticholinergic scales in poly pathological patients","volume":"62","author":"Villalba-Moreno","year":"2016","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.therap.2018.02.010_bib0105","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00228-015-1932-x","article-title":"Different methods, different results \u2013\u00a0how do available methods link a patient's anticholinergic load with adverse outcomes?","volume":"71","author":"Mayer","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2018.02.010_bib0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.161.8.1099","article-title":"Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients","volume":"161","author":"Han","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2018.02.010_bib0120","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1532-5415.2008.02009.x","article-title":"Cumulative anticholinergic exposure is associated with poor memory and executive function in older men","volume":"56","author":"Han","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.02.010_bib0125","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107\u00a0medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.02.010_bib0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2018.02.010_bib0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000325171","article-title":"Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study","volume":"31","author":"Sittironnarit","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.therap.2018.02.010_bib0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.therap.2018.02.010_bib0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.therap.2016.12.010","article-title":"The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings","volume":"72","author":"Briet","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2018.02.010_bib0150","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/gps.4507","article-title":"Anticholinergic effect on cognition (AEC) of drugs commonly used in older people","volume":"32","author":"Bishara","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.therap.2018.02.010_bib0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2018.02.010_bib0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"10.1016\/j.therap.2018.02.010_bib0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.clpt.6100435","article-title":"Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease","volume":"84","author":"Cancelli","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2018.02.010_bib0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/mds.26595","article-title":"Atropinic (anticholinergic) burden in Parkinson's disease","volume":"31","author":"De Germay","year":"2016","journal-title":"Mov Disord Off J"},{"key":"10.1016\/j.therap.2018.02.010_bib0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00228-015-1869-0","article-title":"Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French pharmacovigilance database","volume":"71","author":"Montastruc","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0180","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bcpt.12699","article-title":"A novel scale linking potency and dosage to estimate anticholinergic exposure in older adults: the muscarinic acetylcholinergic receptor antagonist exposure scale","volume":"120","author":"Klamer","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.therap.2018.02.010_bib0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jgs.13206","article-title":"Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people","volume":"63","author":"Salahudeen","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.02.010_bib0190","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1532-5415.2011.03386.x","article-title":"Associations between drug burden index and falls in older people in residential aged care","volume":"59","author":"Wilson","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2018.02.010_bib0195","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/imj.12203","article-title":"Investigating polypharmacy and drug burden index in hospitalised older people","volume":"43","author":"Best","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.therap.2018.02.010_bib0200","doi-asserted-by":"crossref","DOI":"10.1111\/ggi.13234","article-title":"Anticholinergic burden and 1-year mortality among older patients discharged from acute care hospital","author":"Lattanzio","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.therap.2018.02.010_bib0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-016-2162-6","article-title":"Quantification of anticholinergic and sedative drug load with the Drug Burden Index: a review of outcomes and methodological quality of studies","volume":"73","author":"Wouters","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2009.03411.x","article-title":"Drug burden index and physical function in older Australian men","volume":"68","author":"Gnjidic","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0215","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bcpt.12744","article-title":"Anticholinergic exposure in a cohort of adults aged 80\u00a0years and over: associations of the MARANTE scale with mortality and hospitalization","volume":"120","author":"Wauters","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.therap.2018.02.010_bib0220","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00228-015-1919-7","article-title":"Anticholinergic burden in Parkinson's disease inpatients","volume":"71","author":"Lertxundi","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0225","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/bcp.12670","article-title":"Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures","volume":"80","author":"Pont","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.02.010_bib0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jamda.2014.11.017","article-title":"Exposure to atropinic drugs and frailty status","volume":"16","author":"Moulis","year":"2015","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.therap.2018.02.010_bib0235","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/phar.1843","article-title":"Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population","volume":"36","author":"Campbell","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 2","key":"10.1016\/j.therap.2018.02.010_bib0240","first-page":"S277","article-title":"Association between prescribing of anticholinergic medications and incident delirium: a cohort study","volume":"59","author":"Campbell","year":"2011","journal-title":"J Am Geriatr Soc nov"},{"key":"10.1016\/j.therap.2018.02.010_bib0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11598570-000000000-00000","article-title":"Associations between drug burden index and mortality in older people in residential aged care facilities","volume":"29","author":"Wilson","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.therap.2018.02.010_bib0250","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/JCP.0b013e31818ce849","article-title":"Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study","volume":"28","author":"Cancelli","year":"2008","journal-title":"J Clin Psychopharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571830043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571830043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:09Z","timestamp":1758567309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571830043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S004059571830043X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.02.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poids atropinique et m\u00e9dicaments anticholinergiques\u00a0: int\u00e9r\u00eat et application en pratique clinique chez la personne \u00e2g\u00e9e","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}